Decode Health Collaborates with Quest Diagnostics
Collaboration to promote drug and diagnostics R&D in the fields of metabolic disease and autoimmune neurology.
Decode Health has announced a new phase of its collaboration with Quest Diagnostics. In earlier phases of the collaboration, the two parties developed RNA (transcriptome) sequencing capabilities. In this latest phase, the parties have developed a platform for collecting and storing deidentified consented specimens from individuals participating in research.
Read more about the collaboration here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
